自体造血干细胞移植对急性髓系白血病的治疗进展  

Therapy progress of autologous hematopoietic stem cells transplantation on acute myeloid leukemia

作　　者：陈永升[1] 黄琴[1] 尹晓林[1] CHEN Yong-sheng;HUANG Qin;YIN Xiao-lin(Department of Hematology,the 303th Hospital of the People′s Liberation Army,Nanning 530021,China)

机构地区：[1]中国人民解放军第303医院血液科,南宁530021

出　　处：《中国临床新医学》2018年第7期716-720,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：广西卫计委科研课题(编号:Z2014357)

摘　　要：自20世纪80年代至今,自体造血干细胞移植已成为一种治疗急性髓系白血病(AML)的主要疗法。目前自体造血干细胞移植成为因难以找到人类白细胞抗原(HLA)配型相合者而不能行异基因造血干细胞移植的主要治疗手段。该文综述了自体造血干细胞移植在低危、中高危AML及难治性或复发性AML患者中的治疗进展,追踪了降低自体造血干细胞移植治疗AML复发率的策略。Since 1980s,autologous hematopoietic stem cells transplantation(auto-HSCT)has developed as one of the main therapies for hundreds of thousands of patients with acute myeloid leukemia(AML),for whom HLA-matched related donor can not be found and allogeneic hematopoietic stem cell transplantation was not done.This article aims at reviewing the progress of auto-HSCT in treating the AML patients with low,intermediate and high risk factors.and the refractory or recurrent AML,and reviewing the strategy about decreasing the relapse of auto-HSCT therapy.

关 键 词：自体造血干细胞 移植 急性髓系白血病 人类白细胞抗原 

分 类 号：R733.71[医药卫生—肿瘤]